PepGen Inc (PEPG)
13.21
-0.44
(-3.22%)
USD |
NASDAQ |
May 17, 16:00
13.21
0.00 (0.00%)
Pre-Market: 20:00
PepGen SG&A Expense (Quarterly): 5.066M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 5.066M |
| December 31, 2023 | 4.511M |
| September 30, 2023 | 4.24M |
| June 30, 2023 | 4.218M |
| March 31, 2023 | 3.671M |
| December 31, 2022 | 4.047M |
| September 30, 2022 | 3.59M |
| Date | Value |
|---|---|
| June 30, 2022 | 3.401M |
| March 31, 2022 | 3.186M |
| December 31, 2021 | 2.67M |
| September 30, 2021 | 2.366M |
| June 30, 2021 | 1.976M |
| March 31, 2021 | 1.098M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
1.098M
Minimum
Mar 2021
5.066M
Maximum
Mar 2024
3.388M
Average
3.59M
Median
Sep 2022
SG&A Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 46.94M |
| Vertex Pharmaceuticals Inc | 342.70M |
| Sarepta Therapeutics Inc | 127.00M |
| PTC Therapeutics Inc | 73.27M |
| Regenxbio Inc | 18.29M |